Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genus Oncology has dosed the first patient in a Phase I trial to evaluate its compound, GO-203-2c, in patients with solid tumours.
Subscribe to our email newsletter
Genus Oncology has also filed an investigational new drug (IND) application with the US Food & Drug Administration (FDA).
The prospective, open-label Phase I trial is designed to determine the safety and tolerability, and potential anti-tumour activity of GO-203-2c.
The study will enroll up to 40 patients at multiple clinical sites.
GO-203-2c is the optimized lead peptide drug candidate synthesised to target MUC1, an oncoprotein that is over-expressed in many diverse human carcinomas.